These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21852387)

  • 41. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880
    [No Abstract]   [Full Text] [Related]  

  • 42. Bevacizumab therapy for glioblastoma: a passionate discussion.
    Desjardins A; Friedman HS
    CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
    [No Abstract]   [Full Text] [Related]  

  • 43. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
    Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
    Gerstner ER; Emblem KE; Sorensen GA
    Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
    Carbonell WS; DeLay M; Jahangiri A; Park CC; Aghi MK
    Cancer Res; 2013 May; 73(10):3145-54. PubMed ID: 23644530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
    Stupp R; Weller M
    Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
    [No Abstract]   [Full Text] [Related]  

  • 51. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 52. Antiangiogenic therapy for glioblastoma.
    Gerstner ER; Batchelor TT
    Cancer J; 2012; 18(1):45-50. PubMed ID: 22290257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Cloughesy T
    N Engl J Med; 2014 May; 370(21):2049. PubMed ID: 24860870
    [No Abstract]   [Full Text] [Related]  

  • 54. Bevacizumab for newly diagnosed glioblastoma.
    Haines IE; Gabor Miklos GL
    N Engl J Med; 2014 May; 370(21):2048. PubMed ID: 24849089
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D; Nemeskéri C
    Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
    Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
    Clarke JL
    Semin Radiat Oncol; 2014 Oct; 24(4):273-8. PubMed ID: 25219812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
    de Groot J; Reardon DA; Batchelor TT
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
    Burger MC; Breuer S; Cieplik HC; Harter PN; Franz K; Bähr O; Steinbach JP
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.